Clustered mutations within specific protein regions across multiple individuals were identified as described in (21) by querying 1) the number of mutations on the same transcript within the proximity limit (10 amino acids) and 2) the distance between the closest mutations. The resulting mutational clusters were sorted and annotated to identify recurrent mutations in genes with particular relevance to metastatic melanoma.
DNA constructs, viral vectors, shRNAs, and siRNAs
The human RASA1 complementary DNA (cDNA) was purchased from Open Biosystems (BC033015, clone ID# 4829173) and RASA1 Y472H and L481F mutation were introduced with QuickChange XL SiteDirected Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. Coding regions of each wild type and mutants were cloned into the pQCXP-puro-(a gift of Dr. Scott and Dr. Chin) via Gateway cloning system (Invitrogen). pCMV6-XL4-RASA1 was purchased from OriGene. The lentiviral shRNAs in pLKO.1 vector, shRASA1b (5ʹ-CCTGACATCAATAGATTTGAA-3ʹ), shRASA1c (5ʹ-CCCTACATGGAAGGTGTCAAT-3ʹ) were from Open Biosystems. All constructs were sequence verified. The siRNAs targeting RASA1 (SASI-Hs01-00220764 (#764), -00220766 (#766), -00220768 (#768)) were from Sigma-Aldrich, BLOCK-iT (si-Ctrl) from Invitrogen, siR-Ras (A: 5ʹ-CTCGGCCAAACTGCGTCTCAA-3ʹ; B: 5ʹ-CCGGAA ATACCAGGAACAAGA-3ʹ) and AllStars negative control (siCtrl) from Qiagen. siRNA targeting Ral-A (ON-TARGET plus Human RALA(5895) siRNA-SMART pool) was obtained from Dharmacon. Recombinant adenovirus encoding RASA1 or GFP was purchased from Vector Biolabs.
Retrospective melanoma cohort study
Genetic, genomic, clinical, and expression data for archived metastatic melanoma samples were obtained from the Total Cancer Care (TCC) database. TCC analyzed metastatic melanomas from patients treated at the Moffitt Cancer Center for mRNA expression on Affymetrix HuRSTA-2a520709 GeneChips (Affymetrix, Santa Clara, CA) under Liberty IRB#12.11.0023. TCC also performed targeted exome sequencing for 1,403 genes. Age of onset, gender, location of tumor, histological features, and overall survival as well as mutation status and expression level of RASA1 and BRAF mutation status were obtained. Since two probe sets targeted the overlapping regions in exon 24 of RASA1 and showed highly significant positive correlation (r = 0.964, Supplementary Figure S2A ), average intensity of the two RASA1 probe sets was utilized. Overall survival was determined as the length of time (months) from the date of diagnosis for that primary tumor until death or last follow up.
Supplementary Figure S1: Significant clustering of known RASA1 mutations in melanoma. Probability of observing any 5 mutations within a window of 50 amino acids in any location (P) is 0.000965 if 10 mutations are randomly distributed on a protein of 1047 amino acids length. (method) Among 1 to 1047, 10 numbers were randomly selected allowing repeat. These numbers were sorted from smallest to biggest and then distance between Ni and Ni+4 were calculated. Following 10,000 repeats, the data was plotted to show occurrence for each distance between Ni and Ni+4 mutations. Probability was calculated by dividing total number of occurrences that 5 mutations were localized within 50 amino acids window with the total number of any observed occurrences. , wild type (WT), or Y472H mutant RASA1 (n = 7 each). Tumor size was measured every other day with calipers, and tumor volumes were calculated using the formula [Tumor volume (mm 3 ) = (width) 2 × (length) /2]. Repeated ANOVA approach was used to test the time (within-subject factor) and the interaction between group and time (between-subject factor) on tumor volume. The p-value for the time and interaction is 0.002 and 0.047, respectively. When Tukey method to control Type I error inflation was applied to adjust for the multiple comparison, the difference between shCtrl and shRASA1c groups become statistically significant from day 42 (p = 0.048), day 45 (p = 0.042), day 47 (p = 0.035) and up to day 48 (p = 0.038). Tumor volumes were log transformed for the statistical analysis. When Tukey-Kramer method was applied, difference between control (Ctrl) and Y472H group is significant from day 8 (adjusted p < 0.001). Difference of tumor volume between control (Ctrl) and wild type (WT) group is marginally significant on day 15 (adjusted p = 0.055). ) and WM1361A (NRAS Q61K ) with RASA1 over-expression or knock-down, is probed with isoform specific antibodies against H-, K-, N-, and R-Ras or with pan-Ras antibody. Age of diagnosis for primary melanoma, gender, location of metastasis, and histological types are shown for each groups of samples.
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